Argenx to highlight key data and breadth of immunology innovation at 2025 aanem annual meeting and mgfa scientific session

Pivotal adapt seron results and interim adapt jr data showcase vyvgart's potential to treat broad set of myasthenia gravis patients real-world evidence and long-term data reinforce vyvgart's sustained impact on patient outcomes more than 40 abstracts across mg, cidp, mmn, and iim highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities october 15, 2025, 7:00 am cest amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for vyvgart® (iv: efgartigimod alfa-fcab and sc or hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidate empasiprubart at the 2025 american association of neuromuscular & electrodiagnostic medicine (aanem) annual meeting and myasthenia gravis foundation of america (mgfa) scientific session in san francisco from october 29-november 1, 2025. “we're proud to have a robust presence at this year's aanem annual meeting and mgfa scientific session, where we are sharing pivotal data and meaningful evidence across a broad spectrum of serious neuromuscular diseases, including mg, cidp, mmn and iim,” said luc truyen, m.d.
ARGX Ratings Summary
ARGX Quant Ranking